Concepedia

Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease

Koliarne Tong, Daniel Barker, Megan France, Lucy Burr, Hugh Greville, S. Visser, Peter G. Middleton, Claire Wainwright, Douglas J. Dorahy, Peter Wark

Journal of Cystic Fibrosis · 2019 · 22 citations · 13 references

DOI

Concepts

References

13

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>

Claire Wainwright, J.S. Elborn, Bonnie W. Ramsey et al. · New England Journal of Medicine · 2015 · 1.6K citations · Full text

, , +15

Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809

Fredrick Van Goor, Sabine Hadidaꝉ, Peter D. J. Grootenhuis et al. · Proceedings of the National Academy of Sciences · 2011 · 1.1K citations · Full text

, , +13

Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del

Jennifer L. Taylor‐Cousar, À. Munck, Edward F. McKone et al. · New England Journal of Medicine · 2017 · 778 citations · Full text

, , +10

Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis

Katalin Boér, Katherine L. Vandemheen, Elizabeth Tullis et al. · Thorax · 2011 · 274 citations · Full text

, , +14

Factors Influencing Outcomes in Cystic Fibrosis

Charles A. Johnson, Steven M. Butler, Michael W. Konstan et al. · CHEST Journal · 2003 · 223 citations

, , +8